Alcohol use medicines: pharmacology and pharmacy care
Understanding the pharmacological basis of medication-assisted treatment for alcohol use starts by separating three clinical problems: dangerous withdrawal, persistent craving and the risk of returning to heavy drinking. The label can sound as though one drug replaces recovery work, but these medicines work through distinct receptor and enzyme pathways and are most effective when paired with assessment, psychosocial care and follow-up.
Community pharmacists are often the health professionals a person meets most often, making the dispensary a practical setting for explaining treatment, checking interactions and supporting safer drinking goals. Medication-assisted treatment here does not mean medication alone, nor does every person need the same drug. Choice depends on withdrawal risk, liver and kidney function, opioid use, pregnancy, adherence, preference and access to psychological and social support.
The pharmacology behind dependence and relapse
Alcohol initially enhances inhibitory signalling and suppresses excitatory activity. With sustained heavy drinking, the brain adapts: GABA-related inhibition strengthens while glutamate-driven excitation is damped. When alcohol stops abruptly, the adapted system rebounds, producing tremor, anxiety, insomnia, nausea and, in severe cases, seizures or delirium. This neuroadaptation also explains relapse: cues and stress can trigger intense craving before a person consciously chooses to drink.
Because withdrawal, craving and relapse are related but not identical, medicines are used for different purposes. Some reduce neuronal hyperexcitability, some block the reward associated with drinking, and others create an aversive response if alcohol is consumed. None is a universal fix, and benefits are usually measured alongside drinking frequency, quantity, safety and quality of life.
| Medicine | Main pharmacological action | Clinical role | Important cautions |
|---|---|---|---|
| Acamprosate | Modulates glutamatergic NMDA-receptor activity, reducing neuronal hyperexcitability | Helps reduce craving and the likelihood of returning to drinking, especially when paired with psychosocial support | Requires regular dosing; renal impairment changes dosing; diarrhoea is common |
| Naltrexone | Competitive antagonist at mu opioid receptors, reducing the reinforcing effects of alcohol | May reduce craving and heavy-drinking days; oral and depot formulations are used where available | Can precipitate withdrawal in people dependent on opioids; avoid with opioid agonists; monitor liver health |
| Disulfiram | Inhibits aldehyde dehydrogenase, causing acetaldehyde accumulation if alcohol is consumed | Deterrent option for people who can reliably avoid alcohol and attend monitoring | Facial flushing, nausea and headache after exposure; liver toxicity risk and requires careful supervision |
These mechanisms also explain why combining a medicine with counselling is not decorative. A person who feels less driven to drink may be able to attend work, reduce risk to family and engage with treatment for other health needs. Conversely, taking a medicine without a plan for triggers, supports or relapse may produce little sustained benefit.
Matching medicine to withdrawal and relapse risk
Acute withdrawal needs a different response from relapse prevention. In Australia, a person at risk of seizures, delirium or severe confusion needs prompt medical assessment, often through an emergency department, public alcohol service or supervised detox pathway. Benzodiazepine medicines may be used under medical protocols; they are not an appropriate do-it-yourself substitute. Pharmacists should identify red flags during supply and direct the person to urgent care rather than recommend an unsupervised detox.
Acamprosate acts mainly through glutamatergic NMDA-receptor modulation, helping restore a more stable balance in the brain after chronic alcohol exposure. It does not produce a high or cause physical dependence and can be useful where an opioid antagonist is unsuitable. In Australian product information, it is taken three times daily, so missed doses and gastrointestinal effects can affect persistence. Kidney function, rather than liver function, usually determines whether dose adjustment is needed.
Naltrexone blocks mu opioid receptors, which are involved in the reward and reinforcement of drinking. It can reduce craving and the amount consumed, although individual response varies. Oral treatment requires a daily tablet; specialist-coordinated depot injection may be an option where locally available. Crucially, naltrexone can precipitate severe withdrawal in someone physically dependent on opioids and must not be started alongside methadone or buprenorphine without the treating prescriber’s direction.
Disulfiram produces a different, compliance-dependent deterrent. If alcohol is consumed, acetaldehyde causes flushing, throbbing headache, nausea and discomfort. It does not directly reduce craving and is best considered only when the person can maintain abstinence from alcohol while taking it. For co-occurring sexual-health concerns, pharmacists can offer prevention advice and referral; consumer information such as herpes treatment information is most useful when checked against current Australian testing and treatment guidance.
Access pathways across Australia
In Australia, oral medicines for alcohol dependence may be prescribed by a GP or relevant specialist and supplied through a community pharmacy. Acamprosate and naltrexone are available on the Pharmaceutical Benefits Scheme, while disulfiram access and subsidy differ and may involve private prescribing. A prescription with repeats can be dispensed at a “chemist”, as many Australians call their local pharmacy. The PBS co-payment, dispensing fees and any private charges can influence affordability, so a pharmacist should review costs without assuming the patient can simply pay.
The wider pathway is not uniform across states and territories. Public detox and rehabilitation services operate under different arrangements, while GP care, private clinics and local drug and alcohol organisations may share responsibility. In regional and remote areas, including parts of western New South Wales, Western Australia and northern Australia, travel to a service can be a barrier. Telehealth, local stock and a reliable dispensing relationship may matter as much as a metropolitan hospital referral.
Aboriginal communities require services designed with local communities rather than a single national template. Aboriginal Medical Services, Aboriginal Controlled Drug and Alcohol Services and local Aboriginal health workers in places such as Alice Springs and Darwin can support culturally safe assessment, family involvement and treatment that does not treat abstinence as the only measure of success. Close links between the pharmacist, the prescriber and Aboriginal health practitioners can reduce missed doses and help adapt follow-up to local responsibilities, including kinship and community obligations.
Communication is part of access. People may have preferences expressed in more than one language, and accredited interpreters can be booked for consultations where needed. Pharmacy staff should use plain English, ask how a person wants to be addressed and avoid stigmatising labels. The national health advice line, healthdirect on 1800 22 2222, is also a useful source for general health information, while emergencies require 000.
Counselling for adherence, safety and trust
Medication counselling works best when it starts with the person’s goal rather than a lecture about abstinence. Questions can explore what happened after the last lapse, whether craving is strongest at a particular time, and whether side effects, forgetfulness or stigma are getting in the way. Explaining the biological loop can be strengthened by resources on addiction physiology counselling, but the useful conversation remains individual: abstinence may be one goal, while reducing hospital admissions or drinking days is meaningful for others.
Adherence support should match the medicine. For acamprosate, a simple alarm, pill organiser or discussion of renal dosing can make the three-daily schedule workable. Naltrexone counselling should cover the opioid contraindication and what to do if an opioid medicine is needed for pain. With disulfiram, the person needs a clear plan for avoiding hidden alcohol in sauces, medicines or personal products, as well as a way to report illness or unusual symptoms promptly.
Safety review extends beyond alcohol alone. Check other medicines for opioid ingredients, sedatives and hepatotoxic combinations; assess liver disease, kidney impairment, pregnancy and mental-health symptoms; and involve the prescriber when needed rather than altering treatment independently. A person on opioid agonist treatment should never stop methadone or buprenorphine simply to begin naltrexone. Unstable mood or suicidal thinking requires urgent mental-health assessment, while relapse with signs of withdrawal calls for medical review.
Closing the gaps between hospital and community
Hospital care can begin treatment, but the discharge prescription is only useful if the person can access it and know when to take it. A structured handover should state the last alcohol use, withdrawal assessment, medicine start date, dose, monitoring requirements and who will review the plan. The medication-reconciliation lessons in inpatient-outpatient medication transitions are directly relevant: clarify who owns the next action, send the discharge summary promptly and contact the patient or prescriber if there is no response.
Long-term support can be coordinated without making the pharmacist the sole clinician. A practical arrangement may involve monthly medication reviews, three-monthly longer appointments where clinically appropriate, pathology results routed to the prescriber, and brief check-ins with a nurse or peer worker. Community pharmacies can also identify early warning signs, such as repeated early refills, escalating anxiety or renewed heavy drinking, and activate the agreed referral pathway.
Make a standard alcohol-treatment pathway part of routine pharmacy care now: identify eligible patients, offer a private medication review, document consent and preferences, check interactions and organ function, and establish a named GP, alcohol service or Aboriginal health contact for follow-up. Give each person practical written instructions and a plan for managing missed doses, adverse effects and renewed drinking. When the pathway works, the pharmacy becomes a reliable bridge between pharmacology, clinical care and everyday recovery.